The city of Charleston, South Carolina, currently has 3 active clinical trials seeking participants for Diabetes research studies.
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
Recruiting
The goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effective, such a strategy can be used as a therapeutic option for T1D patients and potentially other autoimmune disorders.
Gender:
All
Ages:
Between 18 years and 30 years
Trial Updated:
10/13/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Diabetes Mellitus, Type 1
Effects of GLP-1 Agonists on Gastric Volume
Recruiting
This study will enroll patients ages 18 and over who have a diagnosis of diabetes, are undergoing an elective surgery under general anesthesia and 1) are taking a GLP-1 receptor agonist medication, or 2) not taking a GLP-1 receptor agonist medication. The patients will have a gastric ultrasound prior to surgery to measure any retained gastric contents. The primary goal is to assess the effect of subcutaneous injectable GLP-1 agonists on preoperative gastric volume in fasted, diabetic surgical pa... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Diabetes, Gastric Content Aspiration, Glucagon-like Peptide 1, GLP-1
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among three alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 9,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1:1 allocation to SGLT2i, GLP-1RA, or the c... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
07/25/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Type2Diabetes, ASCVD